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The TP53 tumor suppressor gene is mutated in the
majority of human cancers. Inactivation of p53 in a
variety of animal models results in early-onset tumor-
igenesis, reflecting the importance of p53 as a gate-
keeper tumor suppressor. We generated a mutant
Tp53 allele in the rat using a target-selected mutagen-
esis approach. Here, we report that homozygosity for
this allele results in complete loss of p53 function.
Homozygous mutant rats predominantly develop sar-
comas with an onset of 4 months of age with a high
occurrence of pulmonary metastases. Heterozygous
rats develop sarcomas starting at 8 months of age.
Molecular analysis revealed that these tumors exhibit
a loss-of-heterozygosity of the wild-type Tp53 allele.
These unique features make this rat highly comple-
mentary to other rodent p53 knockout models and a
versatile tool for investigating tumorigenesis pro-
cesses as well as genotoxic studies. (Am J Pathol 2011,
179:1616–1622; DOI: 10.1016/j.ajpath.2011.06.036)
The TP53 gene is arguably the most extensively stud-
ied tumor suppressor and is found mutated in the ma-
jority of human cancers.1,2 To study the in vivo role of
p53 loss in mammalian tumorigenesis, transgenic
mouse models have proven to be extremely useful.
Loss of p53 in mice accelerates neoplasia formation
reflecting strain predispositions, resulting in relatively
uniform tumor spectra with thymic lymphoma as the
1616dominant tumor type.3–6 In human lymphomas, TP53 is
less frequently mutated.7,8 Although lymphomas have
been found in patients with Li-Fraumeni syndrome, who
are born with a defective p53 germ line allele, the
tumor spectrum in these patients is more diverse and
reveals a high frequency of sarcomas.9 This discrep-
ancy can be explained by the fact that human TP53
mutations occur in heterozygous state and loss of the
wild-type allele (loss of heterozygosity [LOH]) has to
precede tumor development. Indeed, heterozygous
mutant p53 mouse models, which require LOH before
tumorigenesis can occur, develop a spectrum of tu-
mors that is more similar to humans. However, this
slows down tumor onset to approximately 9 months of
age,10 increasing the costs of using these models for
the development of therapeutic interventions.
As a mammalian genetic model organism, the rat is
highly complementary to the mouse model and is well-
suited for studying human disease,11 including can-
cer.12–14 Although genetic tools to manipulate the rat
genome have been scarce for a long time, recent tech-
nical developments have enabled a variety of gene tar-
geting methods in rat model systems, including zinc-
finger nuclease (ZFN)-mediated gene targeting15 and
homologous recombination (HR) in embryonic stem (ES)
cells.16 In fact, Tp53 was the first and to date the only
gene that was knocked out in the rat using ES cell-based
HR.16 Although the development of hemangiosarcomas
in these rats was reported in a brief communication while
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has been reported for a P53-deficient rat line until now.
An alternative method for generating rat mutants is
N-ethyl-N-nitrosourea (ENU)-driven target-selected mu-
tagenesis.18,19 This technique is based on treating male
animals with the supermutagen ENU, which very effi-
ciently introduces random point mutations in the DNA of
spermatogenial stem cells. By crossing the ENU-treated
males with untreated females, a F1 library is generated in
which each individual carries unique heterozygous mu-
tations.20 The DNA of the F1 library can then be screened
for mutations in genes of interest that affect protein func-
tion, like the introduction of a premature translation stop.
Using this technique a range of rat knockout models have
been successfully generated,21 including animals defi-
cient for tumor suppressors like Apc,12 Bcra2,13 and
Msh6.14
Here we report the first in-depth characterization of
p53 deficiency in the rat. Homozygous mutant rats com-
pletely lack TP53 protein and display a decrease in sur-
vival as a result of tumorigenesis. However, unlike the
p53 knockout mouse models that primarily develop lym-
phomas, the rat predominantly develops sarcomas, indi-
cating species-specificity in tumor spectrum and demon-strating the importance of the availability and use of
complementary mammalian mutant models. Heterozy-
gous mutant rats exhibit a delay in tumor onset when
compared with homozygous mutant rats, although the
tumor spectrum is not significantly different. Taken to-
gether, the Tp53C273X rat can be a unique and valuable
tool for studying early onset p53-deficient tumor devel-
opment.
Materials and Methods
Animals and Primary Rat Embryonic Fibroblasts
Isolation
All experiments were approved by the Animal Care Com-
mittee of the Royal Dutch Academy of Sciences accord-
ing to the Dutch legal ethical guidelines. Experiments
were designed to minimize the number of required ani-
mals and their suffering. Animals were housed under
standard conditions in groups of two to three per cage
per sex under controlled experimental conditions (12-
hour light/dark cycle, 21  1°C, 60% relative humidity,
Figure 1. A: Schematic representation of the genomic DNA en-
coding rat P53. AnN-ethyl-N-nitrosourea (ENU)-inducedmutation in
the sixth exon of the gene results in a premature stop codon, trun-
cating the protein within the DNA binding domain. The sequence
trace indicates the T to A transition in a heterozygous rat resulting in
a premature stop codon. Asterisk indicates the stopcodon that was
introduced by the ENU-induced mutagenesis. B: Tp53C273X results
in the lack of p53 protein and function in primary rat embryonic
fibroblasts (REFs). Whereas wild-type REFs show p53 stabilization
and translocation to the nucleus on UV radiation, no p53 protein is
observed in homozygous mutant REFs. C: Tp53C273X results in a
complete lack of p53 protein. Wild-type and homozygous mutant
REFs were treated with 0.5 mol/L doxorubicin and lysed at the
indicated time points.Western Blotting reveal the presence of p53 in
wild type REFs, which is stabilized on induction of double strand
breaks, whereas no protein can be detected in homozygous mutant
cells. Notably, the epitopeof the anti-p53monoclonal antibody 1C12
is located N-terminally from the ENU-induced premature transla-
tional stop, demonstrating complete absence of potentially truncated
p53 protein.food and water ad libitum). ENU treatment of male rats
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screened using PCR amplification followed by capillary
sequencing as described.18 For rat embryonic fibroblast
(REF) isolation heterozygous carriers were mated and at
E13.5 embryos were isolated. After washing the embryo
thoroughly, the head and visceral organs were removed
and used for DNA isolation and genotyping. The embryos
were minced and treated with trypsin to get a single cell
suspension. REFs were grown in Dulbecco’s modified
Eagle’s medium supplemented with 10% fetal calf serum.
Histological Analysis
Tissues were sampled and fixed in 4% neutral buffered
formaldehyde and fixed overnight. After routine process-
ing and paraffin embedding, sections of 4–5 m thick-
ness were cut and mounted on glass slides for H&E
staining. For immunohistological stainings, 4 m paraffin
tissue sections were mounted on silan-coated glass mi-
croscope slides, dried overnight at 55°C, and deparaf-
finized in 2  5 minutes xylene, 2  3 minutes 100%
ethanol, 96% or 80% (MyoD-1), 70% ethanol, and rehy-
drated in water. If needed, slides were then pretreated,
blocked with 1:10 normal horse or goat serum in PBS for
15 minutes, and 30 minutes 1% H2O2 in methanol before
incubation with the primary antibodies, Factor VIIIra
(Dako, Heverlee, Belgium), MyoD-1 (Dako), NSE (Lab
Vision Products, Fremont, CA), Synaptophysin (Dako),
CD3 (Cell Marque Corporation, Rocklin, CA), CD79a
(Dako) or Vimentin (Fremont, CA). Slides were three times
rinsed in PBS/Tween and incubated for 30 minutes with
ABC/PO. After rinsing (three times, PBS/Tween), DAB
(500 mg/L in Tris/HCl buffer, pH 7.8  1 mL 35% H2O2;
for MyoD-1: 400 mg/L in Tris/Maleate buffer, pH 7.6 0.2
mL 30% H2O2) was added to visualize immunoreactivity.
LOH Analyses
DNA was isolated from snap-frozen tumor and healthy
tissue of heterozygous mutant animals. Tp53 was ampli-
fied with gene-specific primers encompassing the ENU-
induced knockout allele. The resulting amplicon was re-
sequenced and LOH was determined by genotyping the
knockout mutation.
Results
Tp53C273X Results in a Complete Lack of p53
In an ENU-driven target-selected mutagenesis screen in
the outbred Wistar background, we isolated an F1 animal
carrying a nonsense mutation in the sixth exon of rat Tp53
(Figure 1A). The mutation truncates the protein at the
DNA binding domain, eliminating functionally essential
domains including the nuclear localization domain and
the homo-oligomerization domain. Even when the trun-
cated protein would be stable, it is likely that the mutation
will result in a complete loss of p53 function. To test the
molecular phenotype of Tp53C273X, primary REFs were
isolated and treated with ultraviolet radiation to introducedouble strand breaks in the DNA that will result in p53
stabilization and translocation to the nucleus.23 Whereas
wild-type REFs reveal p53 stabilization and translocation
to the nucleus as expected, no full-length or truncated
p53 could be detected in homozygous mutant REFs (Fig-
ure 1), indicating that Tp53C273X/C273X results in loss of
p53 protein. Furthermore, Western blot analysis of doxo-
rubicin-treated REF lysates confirms complete lack of
p53 in homozygous mutant cells (Figure 1C). Notably, no
Figure 2. Tp53C273X mutant rats demonstrate a decrease in survival as a
result of spontaneous tumor development. A: Homozygous mutant animals
(n  11) have sudden mortality at the age of 4 months, whereas a prolonged
survival is observed in heterozygous carriers (n  8) that reveals a median
survival of approximately 9 months. No wild-type littermates (n 4) became
moribund during this study. B: Pie charts of the tumor types identified in
homozygous (Tp53/) and heterozygous (Tp53/) mutant animals. C:
Tumors in heterozygous (Tp53/) mutant rats display loss of heterozygosity
of the wild-type Tp53 allele (red arrow). Sequencing analysis of DNA
isolated from the ear revealed that the animals were heterozygous carriers of
C273Xthe Tp53 allele; however, loss of the wild-type allele was observed in
tumor tissue.
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fibroblasts, probably due to nonsense-mediated decay of
the mRNA, which has also been observed in other ENU-
induced knockout models.14
p53-Deficient Rats Display Early-Onset
Tumorigenesis
Next, we bred Tp53/C273X to homozygosity by crossing
heterozygous carriers and monitored tumor develop-
ment. As expected, homozygous mutant animals showed
a decrease in survival as a result of early onset tumori-
genesis. Remarkably, almost all Tp53C273X/C273X animals
developed grossly visible tumors or suffered marked
conditional decline around the same time at 4 months of
age (Figure 2A). From the 11 homozygous mutant ani-
mals that were monitored, 10 could be histologically ex-
amined (Figure 2B and Table 1). Hemangiosarcomas, or
pulmonary metastases thereof, were the most frequently
observed neoplasms (7 of 10 animals). Interestingly, one
animal with a hemangiosarcoma also carried a multicen-
tric lymphoma. Hemangiosarcomas were generally com-
posed of plump, spindle-shaped cells growing in bun-
dles and solid sheets, with frequent blood-filled
intercellular spaces (Figure 3A). These hemangiosarco-
mas stained positive for factor VIIIra by immunohisto-
chemistry, confirming an endothelial origin of these neo-
Table 1. Tumor Spectrum in Mutant Tp53 Rats
Rat ID Genotype Sex
Age
(weeks) Tumo
60 / Male 18 Hemangios
B-cell lymp
61 / Male 18 Hemangios
62 / Male 18 Hemangios
66 / Male 20 Adrenocort
76 / Male 26 Hemangios
77 / Male 17 ND‡
140 / Female 22 No tumor d
164 / Male 13 Hemangios
198 / Male 13 Rhabdomyo
undiffere
199 / Male 14 Hemangios
223 / Female 15 Hemangios
9 / Female 36 Rhabdomyo
20 / Female 45 Osteosarco
63 / Male 50 Sarcoma; tr
carcinom
74 / Male 45 No tumor d
75 / Male 40 ND‡
82 / Male 45 Osteosarco
97 / Male 47 Osteosarco
100 / Female 45 Osteosarco
126 / Female 31 No tumor d
*Immunohistochemistry used to determine tumor type.  indicates
means rare marker expression, and — means no marker expression fou
†Primary tumor could not be identified; however multiple pulmonary m
‡Animal was found dead in the cage and in a decomposing state.
ND, not determined; LOH, loss of heterozygosity.plastic cells (Figure 3B). In two animals, tentative primaryhemangiosarcomas were found attached to the wall of a
visceral cavity (thoracic wall and adrenal region, respec-
tively). In these cases the tumor cells formed multilayered
cords; differential diagnoses of transitional cell carci-
noma were deemed less likely based on negative keratin,
and positive vimentin and factor VIIIra immunohistochem-
istry. The rhabdomyosarcoma was grossly found on the
left kidney. The remaining five animals showed multiple
pulmonary metastasis histologically consistent of heman-
giosarcoma, typically located inside, or centered around
blood vessels, indicating extensive hematogenic spread
(Figure 3C), but no primary neoplasm was located. En-
larged spleen and liver in the rat with the hemangiosar-
coma at the thoracic wall were the result of diffuse
lymphoma infiltration (Figure 3D), a second neoplasm
in this animal. Development of lymphoma was re-
stricted to this one homozygous mutant rat and exten-
sive CD79a immunoreactivity indicated this was of B-
cell origin (Figure 3E). Apart from liver and spleen,
lymphoma cells focally invaded the hemangiosarcoma
(Figure 3E). We did not observe involvement of the
thymus, as has been observed in p53 knockout
mice.3–6 Further tumors were detected in two of the
remaining animals: one carried an undifferentiated sar-
coma, which showed immunostaining for MyoD-1, a
skeletal muscle marker; one animal presented with a
large abdominal tumor in the region of the left adrenal.
ose IHC* LOH Metastases
a Factor VIIIra — Lung
CD3; CD79a — Liver
a† Factor VIIIra — Lung
a† Factor VIIIra — Lung
rcinoma NSE; Factor VIIIra-;
Synaptophysin-;
Chromogranin A-
— Lung
a† ND — Lung
— —
— — —
a Factor VIIIra;
Pankeratin-;
Vimentin
— —
ma;
sarcoma
ND — —
a ND — —
a ND — Lung
ma MyoD1; Factor
VIIIra
Yes Lung
ND Yes ND
nal cell
u
ND Yes —
— — —
— ND —
ND Yes Lung
ND Yes Lung
ND Yes —
— — —
nt expression of indicated marker,  indicates moderate expression, 
es were found and used for IHC analyses.r diagn
arcom
homa
arcom
arcom
ical ca
arcom
etected
arcom
sarco
ntiated
arcom
arcom
sarco
ma
ansitio
a in sit
etected
ma
ma
ma
etected
freque
nd.
etastasThe tumor cells were relatively uniform and organized
minera
immun
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masses from endocrine origin (Figure 3F). Some neo-
plastic cells showed immunoreactivity against neuron
specific enolase, synaptophysin, or cromogranin A,
indicating an adrenocortical origin (Figure 3G).
Animals Heterozygous for Tp53C273X Show
Slower Onset and Different Spectrum
Animals heterozygous for Tp53C273X also displayed a
decrease in tumor-free survival compared with wild-type
littermates; however, it was considerably prolonged com-
pared with homozygous mutant littermates (Figure 2A).
This gene dosage effect has also been observed in mu-
tant mouse models and can be attributed to the time
needed to lose the wild-type allele before tumorigenesis
is initiated.5,6 Indeed, LOH was confirmed in the tumors
of all heterozygous animals (Figure 2C and Table 1).
From eight heterozygous animals that were monitored,
seven could be histologically examined. Of these, one
animal presented with hind limb paralysis, but no tumor
was macroscopically detected. Six Tp53/ animals car-
Figure 3. Tp53C273X predominantly develop sarcomas. A: Representative im
morphologically consistent with hemangiosarcoma. B: Marked Factor VIIIra
positivity in pre-existing, non-neoplastic endothelium (internal positive contr
cells with indistinct cell borders and variably sized nuclei. D: Monotonous po
E: Infiltration of neoplastic lymphocytes into a hemangiosarcoma from the sa
the region of the left adrenal. Small polygonal, relatively uniform cells aligned
for neuron-specific enolase was observed in the neoplasm shown in F, consi
rat. Neoplastic spindle cell concentrically arranged around islands of partly
multinucleate cells with rows of nuclei and cytoplasmic and nuclear MyoD1ried sarcomas, all located on the hind limb and in onecase, extending into the abdomen. Four of these could
be further classified as osteosarcomas based on their
histological appearance of pleomorphic spindle cells
with moderate amounts of pale eosinophilic intercellular
material with occasional mineralization (osteoid), some-
times containing osteocytes within lacunae, consistent
with osteosarcoma (Figure 3H). Of the remaining two, one
tumor was classified as rhabdomyosarcoma based on
weak but consistent MyoD-1 (a skeletal muscle marker)
immunostaining (Figure 3I), and inconsistent Factor VIIIra
staining. The final tumor could not be further differenti-
ated. Interestingly, none of these neoplasms in heterozy-
gotes resembled the tumors detected in homozygotes
and pulmonary metastatic spread was observed in only
three animals (50%; Table 1). This underlines a more
aggressive behavior in homozygotes and provides addi-
tional explanation for the reduced survival of homozygote
tumor carriers compared with heterozygous animals. At
the time of finishing this article, three heterozygous car-
riers were still alive (age 12 months). Of the four wild-
type littermates, none became moribund within 12
months, indicating that the early-onset tumorigenesis was
lusters of plump, pleomorphic tumor cells separated by blood-filled spaces,
reactivity in intravascular pulmonary metastasis of hemangiosarcoma. Note
umor emboli in pulmonary blood vessels consist of cells highly pleomorphic
of neoplastic lymphocytes obscuring the normal architecture of the spleen.
al. CD79a immunoreactivity indicates B-cell origin. F: Abdominal mass from
ne fibrovascular stroma as is typical for endocrine tissue. G:Only rare activity
h adrenocortical origin. H: Hind limb neoplasm in heterozygous p53 mutant
lized bone, consistent with osteosarcoma. I: Rhabdomyosarcoma showing
oreactivity.age of c
immuno
ol). C: T
pulation
me anim
along fi
stent wita result of p53 deficiency.
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The ENU-induced Tp53C273X mutation results in a com-
plete loss-of-function phenotype in the rat. At the molec-
ular level we found that no p53 protein could be detected
in homozygous mutant REFs, even after ultraviolet-in-
duced DNA damage, in contrast to wild-type REFs. Con-
sistent with multiple murine p53 knockout models3–6 and
the high prevalence of p53 mutations found in human
tumors,1 p53-deficiency results in an increased tumori-
genesis in rats.
Whereas existing p53-deficient mouse models pre-
dominantly develop lymphomas, our present results indi-
cate that homozygous mutant p53 rats predominantly
develop metastasizing sarcomas, indicating species-
specific phenotypes in different rodent models. Although
the number of animals we followed in this study is rela-
tively low (11 homozygous, 8 heterozygous, and 4 wild-
type animals), the tumor spectrum was very consistent
between all animals, as demonstrated by histological and
immunohistochemical analyses.
Significant phenotypic differences between species
were also observed in the APC mutant rat,12 the BRCA213
and MSH6 knockout rats14 when compared with similar
mouse models. In general, differences in tumor spectra
are observed, like a predominant development of co-
lonic tumors in the APC mutant rat in contrast to a
predominant development of small intestinal tumors in
the Apcmin mouse.12 In addition, the mutant rat models
seem to exhibit increased tolerance to genetically-in-
duced tumorigenesis because APC mutants as well as
MSH6 knockout rats show a delayed onset of tumor
onset and prolonged survival compared with similar
mouse models.12,14 Even more surprising, whereas
BCRA2 mouse knockout mutants are not viable,
BCRA2 knockout rats are viable, although a consider-
able decrease in survival was observed as a result of
increased tumorigenesis.13
Our present observations indicate a similar rate of tu-
mor onset in the rat when compared with p53 knockout
mouse models (tumor onset of 3 to 4 months of age in
mice versus 4 months in rats), and perhaps a slightly
increased rate in heterozygotes. However, the observed
differences in tumor spectra underline the necessity of
interspecies phenotypic comparisons to better under-
stand the in vivo role of p53-deficiency in tumorigenesis.
Interestingly, requirement of loss of heterozygosity sug-
gests that the resulting tumor spectrum in heterozygotes
is mostly dependent on the stochastic distribution of
spontaneous somatic mutations.5 Our present results
suggest a predominance of osteosarcoma in heterozy-
gote p53/C273X rats, whereas early spontaneous tumors
in Han Wistar rats are most frequently lymphomas.24 In
contrast, only a single lymphoma was observed in the
present study, and the predominant occurrence of sar-
comas in both homo-, and heterozygotes suggests an
additional factors may determine the tissue predisposi-
tion of Tp53 C273X –induced tumors.
In summary, our results demonstrate that the
Tp53C273X/C273X rat is highly complementary to existing
mouse models for studying human cancer biology. Thepredominant development of (hemangio)sarcomas in ho-
mozygous mutant rats with a high occurrence of lung
metastases and a relatively early onset of 4 months
makes this rat model a unique and especially useful tool
for testing therapeutic interventions.
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